Merck announces Bovilis Nasalgen 3-PMH is now available for beef and dairy cattle
Bovilis Nasalgen 3-PMH, an intranasal vaccine that protects cattle from several pneumonia-causing pathogens, is now available from Merck.
The vaccine is approved to protect dairy and beef cattle from five of the most common pneumonia-causing viral and bacterial pathogens. According to Merck, this is the first intranasal vaccine effective in providing early, broad-spectrum respiratory protection against both viral and bacterial pathogens in a needle-free, animal- and Beef Quality Assurance-friendly administration.
“Bovilis Nasalgen 3-PMH is a modified-live, intranasal vaccine that stimulates a strong early immune response to help give calves a strong foundation of respiratory disease protection,” said Dr. Scott Nordstrom, director of livestock innovation and discovery at Merck. “Results of efficacy, duration of immunity and safety studies demonstrate the vaccine is safe and effective for calves at 1 week of age or older.”
According to Merck, the vaccine protects against infectious bovine rhinotracheitis, bovine respiratory syncytial virus, parainfluenza 3, Mannheimia haemolytica and Pasteurella multocida.
Cattle veterinarians and producers can now purchase the vaccine, which is administered in a single 2 milliliter dose. It’s been proved safe for use in pregnant cows and in calves nursing pregnant cows, as well as young calves. It’s available in 2 mL, 20 mL and 100 mL packages.